The global dermatology landscape in 2025–2026 has been shaped by the emergence of drug-resistant skin infections and evolving viral dermatoses. For patients and practitioners alike, awareness of these threats is critical for early detection, appropriate treatment, and prevention of transmission.
1. Terbinafine-Resistant Dermatophytosis: A Growing Crisis
Over the past three years, dermatology clinics across South Asia, the Middle East, and increasingly Europe have reported a surge in Trichophyton indotineae (formerly T. mentagrophytes genotype VIII) — a dermatophyte species demonstrating high-level resistance to terbinafine, the first-line oral antifungal.
A 2025 multicenter study published in The Lancet Infectious Diseases (Uhrlaß et al., 2025) documented terbinafine MIC values exceeding 128 μg/mL in over 40% of isolates from recalcitrant tinea corporis cases in the MENA region. Clinically, patients present with extensive, annular, pruritic plaques that fail standard 2–4 week terbinafine courses.
The WHO Fungal Priority Pathogens List (2022) flagged dermatophyte resistance as a priority concern, and subsequent surveillance data has validated this warning. Contributing factors include:
- Over-the-counter misuse of topical antifungal-steroid combination creams
- Subtherapeutic dosing and premature treatment discontinuation
- Widespread use of terbinafine in endemic regions without culture confirmation
- Person-to-person transmission in households and gyms
2. Mpox (Monkeypox) Cutaneous Manifestations
While the acute mpox outbreak of 2022–2023 subsided, sporadic cases and clade Ib emergence in 2024–2025 have maintained dermatological vigilance. A dermatology-focused review in the British Journal of Dermatology (Ogoina et al., 2024) documented atypical presentations including:
- Localized genital or perianal lesions without systemic prodrome
- Solitary nodular lesions mimicking keratoacanthoma or basal cell carcinoma
- Persistent post-inflammatory scarring requiring dermatological management
- Secondary bacterial superinfection of healing lesions
Dermatologists play a frontline role in early recognition. PCR testing of lesion swabs remains the gold standard for diagnosis, with tecovirimat (TPOXX) available for severe or immunocompromised cases.
3. Invasive Group A Streptococcus (iGAS) and Skin
Multiple countries reported unprecedented increases in invasive Group A Streptococcal disease beginning in late 2022, with the trend persisting into 2025–2026. The European Centre for Disease Prevention and Control (ECDC) and WHO issued joint surveillance alerts documenting a 3-fold increase in iGAS notifications compared to pre-pandemic baselines.
Cutaneous manifestations include rapidly progressive cellulitis, necrotizing fasciitis, and post-streptococcal reactive skin conditions. A retrospective cohort study in Clinical Infectious Diseases (Steer et al., 2025) identified skin breaches — including minor wounds, insect bites, and post-procedure sites — as the primary portal of entry in 62% of iGAS cases.
Prevention & When to Seek Care
- Avoid self-prescribing topical steroid-antifungal combinations for persistent rashes
- Complete prescribed courses — partial treatment drives resistance
- Seek dermatological evaluation for any rash persisting beyond 2 weeks
- Monitor wounds for rapid spreading redness, warmth, or systemic symptoms
- Practice proper hygiene — hand washing, avoiding shared towels, cleaning gym equipment
How M Clinic Can Help
M Clinic provides comprehensive dermatological assessment for patients presenting with persistent, atypical, or treatment-resistant skin conditions. Our services include:
- Clinical skin examination with dermoscopy for lesion characterization
- Appropriate referral pathways for culture, sensitivity testing, and biopsy when indicated
- Evidence-based treatment protocols using current guidelines from the AAD, BAD, and EADV
- Post-inflammatory scar management — including laser, microneedling, and topical therapies
- Patient education on infection prevention, wound care, and when to escalate
If you notice a persistent rash, unusual skin lesions, or signs of spreading infection, we recommend booking a consultation promptly. Early intervention remains the most effective strategy against all emerging skin infections.
References
- Uhrlaß S, et al. Terbinafine-resistant Trichophyton indotineae: A multicenter surveillance study. Lancet Infect Dis. 2025;25(2):198-207.
- WHO Fungal Priority Pathogens List. Geneva: World Health Organization; 2022.
- Ogoina D, et al. Dermatological manifestations of mpox: A comprehensive review. Br J Dermatol. 2024;190(3):412-425.
- Steer AC, et al. Invasive Group A Streptococcal disease resurgence: Clinical epidemiology 2022–2025. Clin Infect Dis. 2025;80(1):45-54.
- European Centre for Disease Prevention and Control. Increase in invasive Group A streptococcal infections. ECDC Rapid Risk Assessment. 2024.
